"Immuosuppression and Medications in Children"

The objectives of this lecture will be:

Compare therapeutic effects, drug interactions, and safety of current immunosuppressants used in pediatric solid organ transplant (SOT)
Determine therapeutic goals for individual pediatric SOT recipients with respect to balancing preventing rejection and avoiding infections/complications
Describe preventive and treatment strategies for pediatric SOT complications, including infection, malignancy, linear growth impairment, posttransplant diabetes mellitus, and cardiovascular complications.

Use the markers on the video timeline to quickly navigate to important points in the video outlined below:
- Chapter 1: Objectives [0:34]
- Chapter 2: Introduction/Overview of Immunosuppression [1:06]
- Section A) Review of T-Cell Activation [1:28]
- Section B) Types of Immunosuppression [3:30]
- Chapter 3: Induction Therapy [3:42]
- Section A) Kidney Transplant Guidelines [5:09]
- Section B) Heart Transplant Guidelines [5:59]
- Section C) Liver Transplant Guidelines [6:40]
- Section D) General Discussion on Variation of Induction Strategies [7:07]
- Section E) SRTR Data for Induction [7:55]
- Chapter 4: Maintenance Therapy [9:59]
- Section A) Corticosteroids [12:12]
- Section B) Tacrolimus [13:30]
- Part 1) Strategies for Subtherapeutic Tacrolimus Levels [17:19]
- Part 2) Strategies for Supratherapeutic Tacrolimus Levels [19:15]
- Section C) Cyclosporine [20:34]
- Section D) Calcineurin Inhibitor Adverse Effects [21:14]
- Section E) mTOR Inhibitors [21:59]
- Section F) Anti-Proliferative Agents [23:41]
- Part 1) MPA Monitoring [25:15]
- Chapter 5: Acute Cellular Rejection [26:48]
- Chapter 6: Antibody-Mediated Rejection [28:11]
- Chapter 7: Opportunistic Infections and Post-Transplant Complications [29:55]
- Section A) PCP [30:04]
- Section B) CMV [30:40]
- Section C) Immunizations [32:01]
- Section D) Malignancy [33:08]
- Section E) Endocrine [33:27]
- Section F) Non-Adherence [35:56]
- Section G) Post-Transplant Renal Function [37:34]
- Chapter 8: Pharmacogenomics [40:59]
- Chapter 9: Conclusion [44:07]

Barrett Crowther PharmD, BCPS, FAST

Appearances